Search

US-20260123666-A1 - PODS FOR VAPORIZERS AND SMOKING PRODUCTS

US20260123666A1US 20260123666 A1US20260123666 A1US 20260123666A1US-20260123666-A1

Abstract

Ready-to-vape precision pods and formulations thereof for harm reduction products particularly to assist smokers to quit tobacco products altogether or to switch to a less harmful product such as e-cigarettes or a tobacco heating product.

Inventors

  • Joseph Pandolfino

Assignees

  • CABBACIS LLC

Dates

Publication Date
20260507
Application Date
20260105

Claims (19)

  1. 1 . A ready-to-vape precision pod for use with a vaporizer configured to generate vapor from dry herbs or plant extracts, the ready-to-vape precision pod comprising: at least 5 mg of very low THC Cannabis: at least 5 mg of reconstituted tobacco; a compartment that houses the very low THC Cannabis and the reconstituted tobacco; and one or more vents for ventilation of air and vapor into and out of the compartment, wherein the at least 5 mg very low THC Cannabis comprises a collective THCA/THC content of equal to or less than 3 mg/g and a CBDA content of at least 0.10 mg; wherein the at least 5 mg of reconstituted tobacco comprises a nicotine content of at least 0.10 mg; and wherein CBDA is the most abundant cannabinoid of the at least 5 mg of very low THC Cannabis.
  2. 2 . The precision pod according to claim 1 further comprising at least 0.10 mg of a flavor comprising menthol.
  3. 3 . The ready-to-vape precision pod of claim 1 further comprising at least 0.10 mg of cannabigerovarinic acid (CBGVA).
  4. 4 . The ready-to-vape precision pod of claim 1 further comprising at least 0.10 mg of tetrahydrocannabivarinic acid (THCVA).
  5. 5 . The ready-to-vape precision pod of claim 1 further comprising at least 0.10 mg of cannabigerolic acid (CBGA).
  6. 6 . The ready-to-vape precision pod of claim 1 further comprising at least 0.10 mg of cannabichromenenic acid (CBCA).
  7. 7 . A ready-to-vape precision pod for use with a vaporizer configured to generate vapor from dry herbs or plant extracts, the ready-to-vape precision pod comprising: at least 5 mg of very low THC reconstituted Cannabis: at least 5 mg of tobacco; a compartment that houses the very low THC reconstituted Cannabis and the tobacco; and one or more vents for ventilation of air and vapor into and out of the compartment, wherein the at least 5 mg very low THC reconstituted Cannabis comprises a collective THCA/THC content of equal to or less than 3 mg/g and a CBDA content of at least 0.10 mg; wherein the at least 5 mg of tobacco comprises a nicotine content of at least 0.10 mg; and wherein CBDA is the most abundant cannabinoid of the at least 5 mg of very low THC reconstituted Cannabis.
  8. 8 . The precision pod according to claim 7 further comprising at least 0.10 mg of a flavor comprising menthol.
  9. 9 . The ready-to-vape precision pod of claim 7 further comprising at least 0.10 mg of cannabigerovarinic acid (CBGVA).
  10. 10 . The ready-to-vape precision pod of claim 7 further comprising at least 0.10 mg of tetrahydrocannabivarinic acid (THCVA).
  11. 11 . The ready-to-vape precision pod of claim 7 further comprising at least 0.10 mg of cannabigerolic acid (CBGA).
  12. 12 . The ready-to-vape precision pod of claim 7 further comprising at least 0.10 mg of cannabichromenenic acid (CBCA).
  13. 13 . A ready-to-vape precision pod for use with a vaporizer configured to generate vapor from dry herbs or plant extracts, the ready-to-vape precision pod comprising: at least 5 mg of very low THC Cannabis: at least 5 mg of tobacco; a compartment that houses the very low THC Cannabis and the tobacco; and one or more vents for ventilation of air and vapor into and out of the compartment, wherein the at least 5 mg very low THC Cannabis comprises a collective THCA/THC content of equal to or less than 3 mg/g and a CBGA content of at least 0.10 mg; wherein the at least 5 mg of tobacco comprises a nicotine content of at least 0.10 mg; and wherein CBGA is the most abundant cannabinoid of the at least 5 mg of very low THC Cannabis.
  14. 14 . A ready-to-vape precision pod of claim 13 , wherein the at least 5 mg of tobacco comprises low nicotine tobacco containing a nicotine content of equal to or less than 3 mg/g.
  15. 15 . The precision pod according to claim 13 further comprising at least 0.10 mg of a flavor comprising menthol.
  16. 16 . The ready-to-vape precision pod of claim 13 further comprising at least 0.10 mg of cannabigerovarinic acid (CBGVA).
  17. 17 . The ready-to-vape precision pod of claim 13 further comprising at least 0.10 mg of tetrahydrocannabivarinic acid (THCVA).
  18. 18 . The ready-to-vape precision pod of claim 13 further comprising at least 0.10 mg of cannabidiolic acid (CBDA).
  19. 19 . The ready-to-vape precision pod of claim 13 further comprising at least 0.10 mg of cannabichromenenic acid (CBCA).

Description

CROSS REFERENCE TO RELATED APPLICATIONS The present application is a continuation of U.S. application Ser. No. 17/718,429, filed on Apr. 12, 2022; which is a continuation of U.S. application Ser. No. 17/382,502, filed on Jul. 22, 2021; which is a continuation of U.S. application Ser. No. 16/797,987, filed on Feb. 21, 2020; which is a divisional application of U.S. patent application Ser. No. 16/569,318, filed on Sep. 12, 2019, now U.S. Pat. No. 10,897,925; which is a continuation-in-part application of U.S. patent application Ser. No. 16/178,298, filed on Nov. 1, 2018, now U.S. Pat. No. 10,878,717; which is a continuation of U.S. application Ser. No. 16/047,948, filed on Jul. 27, 2018, in the U.S. Patent and Trademark Office, the disclosures of which are herein incorporated by reference in their entireties. BACKGROUND 1. Field The present disclosure relates to tobacco and cannabis products. 2. Description of the Related Art Tobacco product manufacturers possess the methods and knowhow to produce products with a wide range of nicotine content and alkaloid profiles. For example, they can produce cigarettes ranging from approximately 0.20 mg per cigarette of nicotine to at least 30 mg per cigarette. Very low nicotine cigarettes and low tar-to-nicotine yield-ratio cigarettes are both useful for tobacco harm reduction for different purposes; the former is to quit smoking and tobacco use altogether or transition smokers to smokeless tobacco products, and the latter is to smoke less. The methods and knowhow of tobacco product manufacturers include genetic engineering and plant breeding techniques to decrease or increase nicotine content in tobacco plants. Nicotine can also be extracted from tobacco for production of very low nicotine cigarettes or nicotine can be added for production of low tar-to-nicotine yield-ratio cigarettes. See, for example, U.S. Pat. Nos. 3,612,066, 9,738,622, 9,814,258 and 10,113,174, which describe these methods employed by tobacco product manufacturers to produce factory-made tobacco products. Tobacco end users, on the other hand, do not possess these method or knowhow capabilities; nor have they had devices or the alkaloids in the appropriate formulations to conveniently and economically add alkaloids, cannabinoids, flavors, or other additives to their smoking products, which include cigarettes, cigars and marijuana cigarettes. Some people smoke or vape tobacco and cannabis simultaneously, including those who do not otherwise smoke tobacco, since there are reciprocal and fortifying effects from the combination of the nicotine in tobacco and the cannabinoids in cannabis. Inhaling smoke or vapor is the most efficient and quickest way of experiencing the effects of these compounds, whether tobacco or cannabis is smoked or vaped separately or simultaneously. The main issue with smoking or vaping a blend of tobacco and cannabis is that many non-nicotine and non-cannabinoid compounds must be inhaled along with the nicotine and cannabinoids. This is especially the case when smoking a blend of tobacco and cannabis or smoking cigarettes with any added cannabinoids since in either case, many carcinogenic tobacco compounds must be inhaled concurrently with the nicotine and cannabinoids. Michael Russell, referred to as the father of tobacco harm reduction, famously declared, “People smoke for nicotine but they die from the tar.” However, using tobacco in any form, including in smokeless tobacco products, is not without risk since tobacco contains tobacco-specific nitrosamines (TSNAs), which are carcinogenic, and include N-Nitrosonornicotine (NNN), 4-N-Nitrosomethylamino-1-(3-pyridyl)-1-butanone (NNK), N-Nitrosoanatabine (NAT), and N-Nitrosoanabasine (NAB). U.S. Pat. No. 10,369,178 discloses tobacco products with added cannabinoids; however, this disclosure in no way solves the problem of smokers being exposed to many tobacco carcinogens including TSNAs in order to enjoy the pleasurable effects of consuming nicotine and cannabinoids simultaneously. Nor does the disclosure propose any device that facilitates consumers modifying their factory-made cigarettes. Accordingly, there is a need for products comprising appropriate formulations which enable consumers to (i) conveniently, economically, and precisely customize the nicotine, other alkaloid, and/or flavoring content of their factory-made smoking products and (ii) enjoy the pleasurable combined effects of nicotine, cannabinoids and combinations of other compounds through ready-to-vape and ready-to-smoke precision pods without exposure to other tobacco compounds. SUMMARY According to an embodiment of the disclosure, there is provided an onsert to apply onto, around, or within a smoking product for transferring one or more compounds to mainstream smoke of the smoking product, the onsert including a cellulosic wrapper, an adhesive disposed on the cellulosic wrapper for adhering the onsert to the smoking product, and one or more compounds disposed on t